Literature DB >> 29097358

lncRNA MIAT promotes proliferation and invasion of HCC cells via sponging miR-214.

Xinli Huang1, Yun Gao1, Jianjie Qin1, Sen Lu1.   

Abstract

The aberrant expression of long noncoding RNAs (lncRNAs) has been involved in various human tumors including hepatocellular carcinoma (HCC). Our study aimed to investigate the potential molecular mechanism of lncRNA myocardial infarction-associated transcript (MIAT) in HCC. The expression of MIAT and micro-RNA (miR)-214 in HCC tissues and cells was examined by quantitative real-time PCR, and the levels of enhancer of zeste homolog 2 (EZH2) and β-catenin were detected by Western blot assay. Immunoprecipitation analysis was used to detect the level of H3/H4 histone acetylation. RNA pull-down assay was performed to confirm the targeting regulatory relationship between miR-214 and MIAT. Cell viability, proliferation, and invasion were analyzed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), [3H]thymidine incorporation, and Transwell assays, respectively. BALB/c nude mice were used to establish a hepatocellular carcinoma animal model with subcutaneous injection of SK-HEP-1 cells. Upregulation of MIAT is related to the proliferation and invasion of HCC, and downregulating MIAT expression inhibited HCC cell proliferation and invasion. The H3/H4 histone acetylation level of MIAT promoter in HCC tissues was higher than that in normal tissues. MIAT negatively regulated miR-214 in HCC cells. Inhibition of miR-214 reversed the influence of MIAT downregulation on HCC cell proliferation and invasion. In nude mouse xenograft models, downregulation of MIAT markedly suppressed the tumor growth of HCC via releasing miR-214. In conclusion, lncRNA MIAT promotes the proliferation and invasion of HCC cells through sponging miR-214, which brings a novel target for the therapy and prognosis of hepatocellular carcinoma. NEW & NOTEWORTHY This is the first research showing long noncoding RNA (lncRNA) myocardial infarction-associated transcript (MIAT) to have a regulatory effect on hepatocellular carcinoma. Micro-RNA (miR)-214 could be sponged by MIAT to promote the proliferation and invasion of hepatocellular carcinoma cells. The lncRNA MIAT/miR-214 axis brings a novel insight for the therapy and prognosis of hepatocellular carcinoma.

Entities:  

Keywords:  hepatocellular carcinoma; long noncoding RNA; micro-RNA-214; myocardial infarction-associated transcript

Mesh:

Substances:

Year:  2017        PMID: 29097358     DOI: 10.1152/ajpgi.00242.2017

Source DB:  PubMed          Journal:  Am J Physiol Gastrointest Liver Physiol        ISSN: 0193-1857            Impact factor:   4.052


  41 in total

1.  A somatic mutation-derived LncRNA signatures of genomic instability predicts the prognosis and tumor microenvironment immune characters in hepatocellular carcinoma.

Authors:  Chuan Jin; Jian-Sen Zhao; Xu-Qi Huang; Xian-Zi Yang; Feng Li; Ye Song; Fei-Yu Niu; Jin-Rong Lin; Lei Ma; Yan-Xia Shi; Xiao-Shan Li; Peng Jiang; Sha Gao
Journal:  Hepatol Int       Date:  2022-08-10       Impact factor: 9.029

2.  LncRNA NUTM2A-AS1 aggravates the progression of hepatocellular carcinoma by activating the miR-186-5p/KLF7-mediated Wnt/beta-catenin pathway.

Authors:  Jianwu Long; Longfei Liu; Xuefeng Yang; Xiaojun Zhou; Xianzhou Lu; Lei Qin
Journal:  Hum Cell       Date:  2022-10-15       Impact factor: 4.374

3.  Development and Validation of an Immune-Related Prognostic Signature in Cervical Cancer.

Authors:  Rongjia Su; Chengwen Jin; Hualei Bu; Jiangdong Xiang; Lina Zhou; Chengjuan Jin
Journal:  Front Oncol       Date:  2022-05-16       Impact factor: 5.738

4.  lncRNA MIAT targets miR-411-5p/STAT3/PD-L1 axis mediating hepatocellular carcinoma immune response.

Authors:  Xiaoxia Zhang; Banglun Pan; Jiacheng Qiu; Xiaoling Ke; Shuling Shen; Xiaoqian Wang; Nanhong Tang
Journal:  Int J Exp Pathol       Date:  2022-04-15       Impact factor: 2.793

5.  LncRNA ANCR promotes hepatocellular carcinoma metastasis through upregulating HNRNPA1 expression.

Authors:  Zhili Wen; Lingyan Lian; Hao Ding; Youwen Hu; Zhihua Xiao; Kai Xiong; Qian Yang
Journal:  RNA Biol       Date:  2020-01-02       Impact factor: 4.652

6.  Overexpressing microRNA-203 alleviates myocardial infarction via interacting with long non-coding RNA MIAT and mitochondrial coupling factor 6.

Authors:  Fan Wang; Renliang Yu; Shengnan Wen; Jie Yin; Yugen Shi; Hesheng Hu; Suhua Yan
Journal:  Arch Pharm Res       Date:  2021-05-04       Impact factor: 4.946

7.  Identification of m6A methyltransferase-related lncRNA signature for predicting immunotherapy and prognosis in patients with hepatocellular carcinoma.

Authors:  Lili Li; Rongrong Xie; Guangrong Lu
Journal:  Biosci Rep       Date:  2021-06-25       Impact factor: 3.840

8.  Inhibition of long noncoding RNA cancer susceptibility candidate 7 attenuates hepatocellular carcinoma development by targeting microRNA-30a-5p.

Authors:  Dongsheng Li; Lin Lu; Miaomiao Liu; Jufeng Sun
Journal:  Bioengineered       Date:  2022-04       Impact factor: 6.832

9.  Long non-coding RNA-based signature for predicting prognosis of hepatocellular carcinoma.

Authors:  Jie Cao; Lili Wu; Xin Lei; Keqing Shi; Liang Shi; Yifen Shi
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

10.  Silencing of Long Non-coding RNA MIAT Sensitizes Lung Cancer Cells to Gefitinib by Epigenetically Regulating miR-34a.

Authors:  Yunfeng Fu; Chengyuan Li; Yanwei Luo; Lian Li; Jing Liu; Rong Gui
Journal:  Front Pharmacol       Date:  2018-02-13       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.